The development of GBM is driven by dysregulated signaling pathways, with key oncogenic mechanisms including an aberrant activation of PI3K/Akt and Ras/MEK, and the inactivation of TP53 and p16 (CDKN2A)/RB tumor suppressors [45]. The gene discussed is CDKN2A; the disease is neoplasm.